NCT07056699View on ClinicalTrials.gov

SGLT2i, Pioglitazone, and Ketone Production in T1D

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

June 30, 2027

Conditions
Type1diabetes
Interventions
DRUG

Dapagliflozin 10mg Tab

Dapagliflozin (10 mg/day)

DRUG

Pioglitazone 15 MG and 30mg

Pioglitazone (15 mg/day for 2 weeks, then 30 mg/day for 14 weeks)

OTHER

Placebo

Inert placebo for Pioglitazone

Trial Locations (1)

78229-3900

Texas Diabetes Institute, San Antonio

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER